Obesity is an epidemic and a public health threat. Medical weight management remains one
of the options for the treatment of excess weight and recent advances have revolutionized …

Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Background Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic
polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle …

Background Obesity is a chronic disease that results in substantial global morbidity and
mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic …

BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Importance Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like
peptide-1 analogues available for weight management. Objective To compare the efficacy …